JUNS: חוב לטווח קצר של החברה Jupiter Neurosciences Inc

Jupiter Neurosciences Inc (JUNS) is developing a small molecule platform to combat CNS pathologies and Alzheimer's disease. The GURU.Markets website features a chart of the company's short-term borrowings, which illustrates the risks of underfunding and early-stage research failure, with the value stabilizing at 0.00. The lack of a proprietary product and a reliance on equity offerings render the issuer's financial position extremely unstable.

This indicator measures the volume of liabilities with maturities of up to twelve months, allowing for an assessment of liquidity and the risk of cash shortages. By analyzing fluctuations in short-term debt, an investor can determine the dependence of Jupiter Neurosciences Inc (JUNS) on borrowed capital when financing costly clinical trials for neurological pathology therapies prior to product commercialization.